Ophthalmology

Latest News

CME Content

Community Practice Connections™: 8th Annual School of Nursing Oncology™

Beth Sandy, MSN, CRNP, FAPO; Laura Wood, RN, MSN, OCN; Michael Lai, ARNP; Tiffany Richards, PhD, ANP-BC, AOCNP®; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Megan Wanca, APRN, DNP, FNP-C

Case-based Simulation

SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia

Catherine C. Coombs, MD

In-Person + Virtual Event

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

October 26, 2025

Video

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Video

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Multimedia

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Video

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Eytan M. Stein, MD; Marina Kremyanskaya, MD, PhD; Hannah Levavi, MD

Video

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Rami Komrokji, MD; Maen Hussein, MD

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

Video

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

Craig Emmitt Cole, MD; Sikander Ailawadhi, MD; Irene Ghobrial, MD; Monique Hartley-Brown, MD, MMSc

Multimedia

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Elias Jabbour, MD

Video

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Cristina Gasparetto, MD; Katja Weisel, MD

Video

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Rami S. Komrokji, MD; Ghaith Abu-Zeinah, MD; Gabriela Hobbs, MD; Barbara Mora, MD

Video

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Krina Patel, MD, MSc; Alfred L. Garfall, MD; Ajay K. Nooka, MD, MPH, FACP

Video

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Corey Cutler, MD, MPH, FRCPC; Amin M. Alousi, MD; Yi-Bin Chen, MD; Carrie Lynn Kitko, MD

Video

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Alexey V. Danilov, MD, PhD; Leidy L. Isenalumhe, MD, MS; Lori A. Leslie, MD; Mazyar Shadman, MD, MPH; Jason R. Westin, MD, MS, FACP

Video

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Elias Jabbour, MD; Hagop M. Kantarjian, MD; Aaron Logan, MD, PhD, MPhil; Rob Pieters, MD, PhD; Claire Roddie, MD, PhD

Video

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

Catherine C. Coombs, MD, MS; Paolo Ghia, MD, PhD; Tycel J. Phillips, MD; Jeffrey V. Matous, MD; Grzegorz S. Nowakowski, MD, FASCO

Case-based Simulation

SimulatEd™ in Multiple Myeloma: Personalizing Care Plans to Treat Newly Diagnosed Patients

Amrita Krishnan, MD

In-Person Event

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

February 26-28, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Video

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

André H. Goy, MD; Jorge E. Cortes, MD; Sagar Lonial, MD, FACP

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

In-Person Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11, 2026

Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Amrita Krishnan, MD; Meletios Athanasios (Thanos) C. Dimopoulos, MD; Shaji Kumar, MD; Katja Weisel, MD

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multi-Characteristic Opsin Optogenetic Therapy Meets Phase 2 Endpoint in Retinitis Pigmentosa

ByVictoria Johnson

March 30th 2023

Most patients with RP treated with MCO-010 had clinically meaningful improvements in vision.

Around the Helix: Cell and Gene Therapy Company Updates – March 29, 2023

ByNoah Stansfield

March 29th 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Gene Therapy to be Assessed in Pediatric Patients With LCA, Retinitis Pigmentosa

ByVictoria Johnson

March 28th 2023

OCU400 is also being evaluated in other retinal degeneration indications.

ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Study

ByNoah Stansfield

March 17th 2023

Intergalactic Therapeutics’ IG-002 utilizes a proprietary non-viral delivery method.

Around the Helix: Cell and Gene Therapy Company Updates – March 15, 2023

ByNoah Stansfield

March 15th 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

LHON Gene Therapy Continues to Show Efficacy and Safety at 3 Years Post-treatment

ByNoah Stansfield

March 14th 2023

GenSight Biologics reported that 73% of patients treated bilaterally with Lumevoq improved at least +15 ETDRS letters relative to their worst recorded BCVA.

Gene Therapy May Improve Vision in XLRP, Further Research Needed

ByConnor Iapoce

March 11th 2023

Serious adverse events of reduced visual acuity and eye inflammation were observed in 2 clinical trials.

Around the Helix: Cell and Gene Therapy Company Updates – March 8, 2023

ByNoah Stansfield

March 8th 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

LHON-ND4 Gene Therapy Trial Completes Enrollment

ByVictoria Johnson

March 6th 2023

NR082 is being evaluated in a phase 1/2/3 clinical trial in patients with Leber hereditary optical neuropathy.

Around the Helix: Cell and Gene Therapy Company Updates – March 1, 2023

ByNoah Stansfield

March 1st 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 22, 2023

ByNoah Stansfield

February 22nd 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 15, 2023

ByNoah Stansfield

February 15th 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

HHS, CMS to Promote Model for Improved Access to Cell and Gene Therapies, Urge Accelerated Approval Trials to Completion

ByVictoria Johnson

February 15th 2023

A third price model to be tested will limit the price of generic drugs for chronic conditions to $2 under Medicare plan D.

Wet AMD Gene Therapy Trial Demonstrates Consistent Safety and Efficacy With New Manufacturing Process

ByNoah Stansfield

February 13th 2023

No serious adverse events deemed related to RGX-314 occurred in the treated patients.

Gene Therapy Continues to be Well-Tolerated in Retinitis Pigmentosa

ByVictoria Johnson

February 13th 2023

Encouraging efficacy signals have also been observed in treated participants.

CGTLive’s Weekly Rewind – February 10, 2023

ByCGTLive Staff

February 10th 2023

Review top news and interview highlights from the week ending February 10, 2023.

Around the Helix: Cell and Gene Therapy Company Updates – February 8, 2023

ByNoah Stansfield

February 8th 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Preclinical AMD Gene Therapy Shows Potential for Other Retinal Diseases

ByDavid Hutton

February 8th 2023

The new findings are consistent with previous research, in which ophNdi1 demonstrated benefit in AMD models.

IND for Gene Replacement Therapy for Inherited Retinal Dystrophy Cleared by FDA

ByMartin Harp

February 5th 2023

The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.

CGTLive’s Weekly Rewind – February 3, 2023

ByCGTLive Staff

February 3rd 2023

Review top news and interview highlights from the week ending February 3, 2023.

FDA Blocks 4D’s Gene Therapy Program for Fabry, Clears IND for Diabetic Macular Edema

ByVictoria Johnson

February 3rd 2023

The clinical hold comes a few weeks after the company announced it was stopping enrollment in the phase 1/2 clinical trial.

Gene Therapy Trial Doses First Patient With Wet AMD in China

ByVictoria Johnson

February 3rd 2023

The phase 1 clinical trial is the second of Frontera’s trials to begin dosing in 2023.

Around the Helix: Cell and Gene Therapy Company Updates – February 1, 2023

ByNoah Stansfield

February 1st 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Multi-characteristic Opsin Gene Therapy Gets Second Fast Track for Retinal Degenerative Diseases

ByVictoria Johnson

January 31st 2023

MCO-010 is in phase 2 clinical trials for treating retinitis pigmentosa and Stargardt disease.

Around the Helix: Cell and Gene Therapy Company Updates – January 25, 2023

ByNoah Stansfield

January 25th 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Ophthalmology

Latest News

CME Content

Community Practice Connections™: 8th Annual School of Nursing Oncology™

SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

SimulatEd™ in Multiple Myeloma: Personalizing Care Plans to Treat Newly Diagnosed Patients

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Multi-Characteristic Opsin Optogenetic Therapy Meets Phase 2 Endpoint in Retinitis Pigmentosa

Around the Helix: Cell and Gene Therapy Company Updates – March 29, 2023

Gene Therapy to be Assessed in Pediatric Patients With LCA, Retinitis Pigmentosa

ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Study

Around the Helix: Cell and Gene Therapy Company Updates – March 15, 2023

LHON Gene Therapy Continues to Show Efficacy and Safety at 3 Years Post-treatment

Gene Therapy May Improve Vision in XLRP, Further Research Needed

Around the Helix: Cell and Gene Therapy Company Updates – March 8, 2023

LHON-ND4 Gene Therapy Trial Completes Enrollment

Around the Helix: Cell and Gene Therapy Company Updates – March 1, 2023

Around the Helix: Cell and Gene Therapy Company Updates – February 22, 2023

Around the Helix: Cell and Gene Therapy Company Updates – February 15, 2023

HHS, CMS to Promote Model for Improved Access to Cell and Gene Therapies, Urge Accelerated Approval Trials to Completion

Wet AMD Gene Therapy Trial Demonstrates Consistent Safety and Efficacy With New Manufacturing Process

Gene Therapy Continues to be Well-Tolerated in Retinitis Pigmentosa

CGTLive’s Weekly Rewind – February 10, 2023

Around the Helix: Cell and Gene Therapy Company Updates – February 8, 2023

Preclinical AMD Gene Therapy Shows Potential for Other Retinal Diseases

IND for Gene Replacement Therapy for Inherited Retinal Dystrophy Cleared by FDA

CGTLive’s Weekly Rewind – February 3, 2023

FDA Blocks 4D’s Gene Therapy Program for Fabry, Clears IND for Diabetic Macular Edema

Gene Therapy Trial Doses First Patient With Wet AMD in China

Around the Helix: Cell and Gene Therapy Company Updates – February 1, 2023

Multi-characteristic Opsin Gene Therapy Gets Second Fast Track for Retinal Degenerative Diseases

Around the Helix: Cell and Gene Therapy Company Updates – January 25, 2023

Trending on CGTlive®

Data Roundup: September 2025 Features Updates from Huntington Disease Gene Therapy Trial, Pivotal MPS II Gene Therapy Study, and More

Around the Helix: Cell and Gene Therapy Company Updates – October 1, 2025

Umoja Biopharma's In Situ CAR-T Therapy UB-VV111 Fast Tracked for Several R/R B-Cell Malignancy Indications